Jay M Moyes joins Sera Prognostics as it transitions from rigorous scientific and groundbreaking clinical-stage company into a rapidly growing commercial organization.
For more than two decades, Jay Moyes has served in C-level executive and board positions of both private and public companies. He currently serves as Director on the public boards of Achieve Life Sciences (NASDAQ: ACHV), BioCardia (NASDAQ: BCDA) and Puma Biotechnologies (NASDAQ: PBYI). Previous roles include board director service with Predictive Technology Group (PRED); Osiris Therapeutics (OSIR); and Integrated Diagnostics (acquired by Biodesix). Jay also served as Chief Financial Officer and Director of the publicly traded biomaterials company, Amedica Corporation (now SINTX Technologies), managing the company’s IPO and listing on NASDAQ; and as Chief Financial Officer at XDx (now CareDx – CDNA).
At Myriad Genetics (MYGN) , Jay led the finance function for 14 years from the company’s early private stage development beginning with 7 employees, through its successful IPO in 1996, and serving until 2007 as Chief Financial Officer during Myriad’s rapid growth trajectory to become one of the world’s most highly profitable molecular diagnostics companies, with over 900 employees. During that time, Moyes spearheaded the efforts in raising more than $500 million in public and private financings.
“I am thrilled to be working with Jay Moyes again, as we build Sera Prognostics into a highly successful and profitable enterprise,” said Gregory C. Critchfield, MD., MS, chairman and CEO. “Jay’s deep financing connections and expertise in leading biopharmaceutical, medical device and diagnostics companies, both in private and public company settings, will help Sera to achieve its vision of improving the health of mothers and babies and reducing the costs of healthcare delivery.”
Sera has achieved remarkable progress in building a world-class approach to address the immense burden of premature birth,” said Jay Moyes. “The early data from outcome study reports show that Sera’s PreTRM® strategy works, and that by improving the health of women and babies, the enormous personal, societal and economic consequences of prematurity can be mitigated. I am excited to join the talented Sera team and help accelerate the company’s progress, as Greg and I successfully did together at Myriad.”